Description

Zejula (Niraparib): An Overview

Zejula (niraparib) is an oral prescription medication used in the treatment of certain types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It belongs to a class of targeted therapies known as PARP (Poly ADP-Ribose Polymerase) inhibitors, which work by interfering with the ability of cancer cells to repair damaged DNA. As a result, cancer cells become more vulnerable and may stop growing or die.

Zejula is primarily used as a maintenance treatment for patients whose cancer has responded completely or partially to platinum-based chemotherapy. Maintenance therapy aims to help delay cancer recurrence and extend the period during which the disease remains under control.

One of the key advantages of Zejula is its convenient once-daily oral administration, allowing patients to continue treatment at home rather than requiring frequent hospital visits. The medication has been approved for specific ovarian cancer settings, including advanced ovarian cancer associated with certain genetic characteristics such as BRCA mutations or homologous recombination deficiency (HRD). Treatment eligibility is determined by a healthcare professional based on individual patient factors and diagnostic testing.

Like all cancer therapies, Zejula may cause side effects. Common side effects include nausea, fatigue, decreased appetite, constipation, anemia, and low platelet counts. In some cases, more serious adverse effects such as bone marrow disorders may occur, requiring regular monitoring through blood tests and medical follow-up. Patients should discuss potential risks and benefits with their healthcare team before starting treatment.

Clinical studies have demonstrated that Zejula can help prolong progression-free survival in appropriate patients, making it an important option in the management of ovarian cancer. As part of a comprehensive treatment plan, Zejula offers many patients an opportunity to maintain disease control and potentially improve long-term outcomes.